ProBioGen and Life Technologies Present Freedom™ CHO-S™ Platform

Complete the form below to unlock access to ALL audio articles.
ProBioGen AG and Life Technologies Corporation announce the launch of the new Freedom™ CHO-S™ Kit as the result of a successful co-development.
The kit was built for developing stable high yield production cell lines in less than 4 months, and is based on Life Technologies’ CHO-S™ Cells.
The Freedom™ CHO-S™ Kit platform enables end-users the cost- and time-efficient creation of stable cell lines for research and commercial purposes.
The kit’s applicability and efficiency was confirmed in several studies, in which antibody titers of 1 to 3 g/L have been obtained.